Aclara Research Leads Medical Cannabis Industry with Release of Largest Illinois Patient Study
CHICAGO, May 23, 2017 (GLOBE NEWSWIRE) — Aclara Research, a leader in the development of patient and consumer insights within the medical cannabis industry, today released the results of The Illinois Medical Cannabis Patient Experience Study – the first of Illinois patients since the inception of the pilot program in 2012. The study is the largest and most comprehensive look at the impact of the statewide program, examining nearly 300 of the 18,000 Illinois residents registered.
The Aclara Research study found that 86 percent of survey respondents are managing leading symptoms of chronic pain. While chronic pain is not one of the 41 qualifying conditions in Illinois, cannabis shows strong potential in treating autoimmune diseases in which chronic inflammation plays a central role.